Comparison
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates the pituitary to produce GH in a pulsatile, physiological pattern. Recombinant HGH (somatropin) is a prescription pharmaceutical that directly supplies exogenous growth hormone. Unlike many GH axis comparisons, ipamorelin and HGH are frequently used together rather than as alternatives, given their complementary mechanisms.
| Attribute | Ipamorelin | HGH (Somatropin) |
|---|---|---|
| Class | GHRP; selective GHS-R1a agonist (5 amino acids) | Recombinant human growth hormone; prescription pharmaceutical |
| Mechanism | GHS-R1a agonist; stimulates pituitary GH pulse; minimal cortisol or prolactin elevation | Directly activates GH receptor; bypasses pituitary; suppresses endogenous GH production |
| Route | Subcutaneous injection; 1–3× daily | Subcutaneous or intramuscular injection; once daily |
| Half-life | ~2 hours | ~15–20 minutes plasma; tissue effects persist several hours |
| Commonly reported doses | 100–300 mcg SC, 1–3× daily | 1–4 IU SC or IM, once daily (prescription-dependent) |
| Pituitary axis | Preserved; pituitary continues secreting GH physiologically | Suppressed over time by negative feedback from elevated GH and IGF-1 |
| Cortisol / prolactin | Minimal; ipamorelin's defining selectivity characteristic | Not meaningfully affected by direct GH receptor activation |
| Regulatory status | Not FDA-approved; research compound | FDA-approved prescription drug for multiple indications |
The core distinction is indirect pituitary stimulation versus direct GH replacement. Ipamorelin acts upstream, triggering the pituitary's own GH release machinery. The GH pulse produced is pulsatile, physiological in rhythm, and subject to natural feedback controls, including somatostatin suppression and IGF-1 negative feedback. These regulatory features cap the magnitude of GH output, which is a safety characteristic. Exogenous HGH bypasses these controls entirely, delivering a precise, dose-dependent GH load directly to GH receptors throughout the body.
Ipamorelin's defining pharmacological property is selectivity: it stimulates GH with minimal elevation of cortisol, prolactin, or ACTH. This selectivity was the primary design objective when ipamorelin was developed, distinguishing it from older GHRPs that produced significant off-target hormone elevations. Exogenous HGH has no cortisol or prolactin interactions at all, since it acts at GH receptors specifically.
The dosing schedule differs meaningfully. Ipamorelin's 2-hour half-life means multiple daily injections are required for sustained GH axis stimulation. HGH is typically injected once daily. This injection burden is often cited in anecdotal accounts as a practical consideration when choosing between peptide-based GH stimulation and direct HGH replacement. HGH is a prescription pharmaceutical; its use outside approved medical indications requires a physician prescription in most jurisdictions.
Ipamorelin is a pentapeptide GHRP that selectively agonises the GHS-R1a (ghrelin receptor) on pituitary somatotrophs. GHS-R1a activation triggers GH release independently of the GHRH receptor pathway, meaning GHRPs and GHRH analogues (like sermorelin or CJC-1295) stimulate GH through distinct mechanisms and can be combined for synergistic effects. Ipamorelin's selectivity means its GH stimulation is not accompanied by the cortisol, prolactin, or ACTH elevation seen with hexarelin, GHRP-2, or GHRP-6.
Exogenous HGH delivers 191-amino acid somatropin that is structurally identical to endogenous GH. It activates GH receptors in the liver (stimulating IGF-1 production), muscle, adipose tissue, and other peripheral tissues. Because GH and IGF-1 are elevated by exogenous supply rather than pituitary release, the normal pulsatile pattern is disrupted and the feedback system progressively suppresses the pituitary's own secretory activity during chronic use.
Ipamorelin: commonly reported research doses range from 100 to 300 mcg per injection, subcutaneous, administered 1 to 3 times daily. Most anecdotal community reports combine ipamorelin with a GHRH analogue (CJC-1295 or sermorelin) to exploit the synergistic GHRH-receptor plus GHS-R1a dual stimulation pathway.
HGH: prescription dosing varies by indication and physician determination. Research community protocols commonly cite 1 to 4 IU once daily subcutaneously, often in the morning or post-exercise. HGH is a prescription pharmaceutical and dosing outside physician supervision carries regulatory and safety implications.
Ipamorelin reported side effects include transient flushing, mild headache, and injection site reactions. The absence of significant cortisol or prolactin elevation is a pharmacological characteristic rather than a side effect, and is considered an advantage over non-selective GHRPs.
HGH reported side effects include fluid retention (edema), joint and muscle pain, carpal tunnel syndrome, blood glucose elevation (GH is insulin-antagonising), and at chronic supraphysiological doses, features associated with acromegaly. These effects are dose-dependent and more prominent at research doses above the therapeutic prescription range.
Ipamorelin and HGH are sometimes combined in anecdotal community protocols, and there is a mechanistic rationale for this unlike most GH axis compound combinations. Ipamorelin stimulates endogenous pituitary GH production via GHS-R1a, while exogenous HGH acts at peripheral GH receptors directly. These pathways are not redundant in the same way that two compounds acting on the same receptor would be.
However, the practical benefit is debated. Elevated GH and IGF-1 from exogenous HGH will reduce the pituitary's responsiveness to ipamorelin's stimulation through negative feedback. The combined approach involves more injections, higher cost, and potential additive side effects (fluid retention, insulin resistance). Anecdotal reports most commonly describe ipamorelin and HGH as alternatives rather than stack components, with ipamorelin favoured for its pituitary-preserving, lower-cost, physiological profile and HGH for cases requiring more direct, dose-precise GH replacement.
Research contexts commonly favour ipamorelin when pituitary function is intact, pulsatile physiological GH release is preferred, cost and regulatory accessibility are considerations, or when the selectivity profile (no cortisol/prolactin elevation) is relevant to the research design. Ipamorelin is most commonly reported as part of a stack with a GHRH analogue (CJC-1295 or sermorelin) rather than as a sole GH-raising agent.
Research contexts favouring HGH include cases where the pituitary is deficient or where dose-precise, prescription-grade GH replacement is required. Its FDA-approved indications include adult GH deficiency, short stature, and cachexia. HGH is a prescription pharmaceutical; its use requires physician prescription in most jurisdictions.
The research evidence base for direct comparison is limited. Ipamorelin raises GH and IGF-1 indirectly and cannot exceed the physiological ceiling imposed by negative feedback. Exogenous HGH at supraphysiological doses can raise IGF-1 substantially higher than pituitary stimulation typically achieves. Anecdotal reports suggest ipamorelin produces more modest body composition changes than pharmaceutical HGH doses used in research community contexts, but with a more favorable side effect profile and lower injection burden.
No. Ipamorelin stimulates pituitary GH secretion; it does not suppress it. The modest IGF-1 elevation from ipamorelin will slightly increase negative feedback on GH secretion, but ipamorelin's GHS-R1a stimulation overrides this within the physiological range. Exogenous HGH causes more significant endogenous GH suppression because elevated circulating GH directly inhibits pituitary somatotroph activity via somatostatin and IGF-1 feedback.
Ipamorelin is most commonly reported in combination with a GHRH analogue such as CJC-1295 or sermorelin. The combination exploits two distinct receptor pathways in the pituitary: GHS-R1a (ipamorelin) and the GHRH receptor (CJC-1295/sermorelin). Research has shown this dual stimulation produces synergistic GH pulse amplification beyond what either compound achieves alone.
HGH (somatropin) is an FDA-approved pharmaceutical drug with established indications and a regulatory history. In most jurisdictions, it is classified as a prescription-only medicine. Ipamorelin is a research peptide without FDA approval, which places it outside the pharmaceutical drug regulatory framework. This does not mean ipamorelin is without risk; it means it occupies a different regulatory category that varies by jurisdiction.